Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer

PHASE2CompletedINTERVENTIONAL

Timeline

Start Date

January 31, 2000

Study Completion Date

May 31, 2004

Conditions

Drug/Agent Toxicity by Tissue/OrganLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmOral ComplicationsRadiation Toxicity

Interventions

BIOLOGICAL

filgrastim

BIOLOGICAL

palifermin

DRUG

cyclophosphamide

DRUG

etoposide

DRUG

ifosfamide

PROCEDURE

quality-of-life assessment

RADIATION

radiation therapy

Trial Locations (1)

Jonsson Comprehensive Cancer Center, UCLA, Los Angeles

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

Jonsson Comprehensive Cancer Center

OTHER

NCT00004132 - Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | Biotech Hunter | Biotech Hunter